Showing results (261-270 of 315) with videos related to

Sort By:
Pageof 32
European Journal of Cancer (Oxford, England : 1990)|November 13, 2013
Brostallicin versus doxorubicin as first-line chemotherapy in patients with advanced or metastatic soft tissue sarcoma: an European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group randomised phase II and pharmacogenetic studyH Gelderblom, J Y Blay, B M Seddon, et al.
British Journal of Cancer|February 5, 2009
Gemcitabine-oxaliplatin combination for ovarian cancer resistant to taxane-platinum treatment: a phase II study from the GINECO groupI Ray-Coquard, B Weber, J Cretin, et al.
Microbiology Resource Announcements|March 6, 2024
Genome sequences of actinobacteriophages JorRay, Blocker23, Nibbles, and OlgasCloverBreanna M Baumgartner, Kayla A Bono, Dawn R McIntosh, et al.
European Journal of Cancer (Oxford, England : 1990)|December 14, 2019
A phase II of gemcitabine combined with pazopanib followed by pazopanib maintenance, as second-line treatment in patients with advanced leiomyosarcomas: A unicancer French Sarcoma Group study (LMS03 study)P Pautier, N Penel, I Ray-Coquard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 2, 2020
ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancerR E Miller, A Leary, C L Scott, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 15, 2014
Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: a randomized controlled open-label trialA Adenis, J-Y Blay, B Bui-Nguyen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 4, 2017
Phase II randomized study of PM01183 versus topotecan in patients with platinum-resistant/refractory advanced ovarian cancerA Poveda, J M Del Campo, I Ray-Coquard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 1, 2024
The efficacy and safety of mirvetuximab soravtansine in FRα-positive, third-line and later, recurrent platinum-sensitive ovarian cancer: the single-arm phase II PICCOLO trialA Alvarez Secord, S N Lewin, C G Murphy, et al.
ESMO Open|September 18, 2025
Real-world treatment patterns and effectiveness after disease progression on CDK4/6 inhibitors for HR-positive/HER2-negative metastatic breast cancer in the ESME-MBC cohortR Varnier, D Pérol, W Jacot, et al.
Biology of Reproduction|March 21, 2026
Reduced fertility induced by MASLD in female mice is improved by Senolytic treatmentJéssica D Hense, José V V Isola, Driele N Garcia, et al.
Pageof 32